Publications & Presentations

pz-cel / EB-101

Long-Term Safety of Prademagene Zamikeracel (Pz-cel) in Recessive Dystrophic Epidermolysis Bullosa (RDEB) | Society for Investigative Dermatology (SID) 2026 Annual Meeting | May 15, 2026

Sustained Wound Healing and Long-Term Safety of Prademagene Zamikeracel (Pz-cel) in Recessive Dystrophic Epidermolysis Bullosa (RDEB): Five-Year Results from the VIITAL Phase 3 Trial

View Poster

Publication of Full Data | The Lancet | May 2025 (Published)

Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa Wounds (VIITAL™): A Two-Centre, Randomised, Open-Label, Intrapatient-Controlled Phase 3 Trial

Press Release Summary

Publication of Full Data | Orphanet Journal of Rare Diseases | October 17, 2022

Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa

Publication